Abstract:Ezrin, a member of the ezrin/radixin/moesin (ERM) protein family, plays an important role in tumor metastasis. Accumulating studies demonstrated that a high expression level of human ezrin has been correlated with numerous human malignancies. This study was aimed to explore the clinicopathological significance of ezrin protein expression in pancreatic ductal adenocarcinomas (PDAC), and to further identify its role as a potential biomarker and therapeutic target of PDAC. Immunohistochemical (IHC) staining of ezrin protein was performed on 106 PDAC tissue samples and 37 adjacent and 21 normal pancreatic tissue samples. Additionally, localization of ezrin protein in Panc-1 PDAC cell line was observed using immunofluorescence (IF) staining. The correlation between ezrin overexpression and the clinicopathological features of PDAC was evaluated using Chi-square test, and differences in survival curves were analyzed using log-rank tests. In results, ezrin protein is widely distributed in the cytoplasm and membrane of PDAC cells by IHC and IF staining, but some cases showed a cell membrane staining pattern. The positive rate of ezrin protein expression was 82.1% (87/106) in PDAC, which was significantly higher than it in either adjacent pancreatic tissues (37.8%, 14/37) or normal pancreatic tissues (19.0%, 4/21). Overexpression of ezrin was closely related with larger tumor size, positive lymph node metastasis and advanced clinical stage. However, it was not correlated with patient age, gender, differentiation, Ki-67 expression index, and pancreas calcification point. Survival analysis showed that patients with ezrin high expression level had significantly lower overall survival rate than that with ezrin low expression level. Importantly, further analysis using a Cox proportional hazard regression model revealed that high ezrin expression emerged as a significant independent hazard factor for overall survival rates of patients with PDAC along with lymph node metastasis and TNM stage. In conclusion, ezrin protein played an important role in the progression of PDAC, and the overexpression of ezrin protein might be a useful prognostic marker of PDAC.

Ezrin contributes to cervical cancer progression through induction of epithelial-mesenchymal transition.

Acetylation of Ezrin Regulates Membrane-Cytoskeleton Interaction Underlying CCL18-elicited Cell Migration.

Ezrin T567 phosphorylation regulates migration and invasion of ectopic endometrial stromal cells by changing actin cytoskeleton

High expression of ezrin predicts poor prognosis in uterine cervical cancer

Expression and clinical significance of ezrin in non--small-cell lung cancer.

Ezrin Promotes Breast Cancer Progression by Modulating AKT Signals

Ezrin/NF-kB Activation Regulates Epithelial- Mesenchymal Transition Induced by EGF and Promotes Metastasis of Colorectal Cancer.

A Microrna Contribution to Aberrant Ras Activation in Gastric Cancer.

Relationship of Ezrin protein and cancer metastasis

Membrane-cytoskeleton linker protein ezrin expression in renal cell carcinoma and its relation to tumor metastasis and tumor invasion

Ezrin is Associated with Gastric Cancer Progression and Prognosis

Association of Ezrin Expression with the Progression and Prognosis of Gastrointestinal Cancer: a Meta-Analysis

Ezrin Promotes Esophageal Squamous Cell Carcinoma Progression Via the Hippo Signaling Pathway.

Ezrin Protein Overexpression Predicts the Poor Prognosis of Pancreatic Ductal Adenocarcinomas.

Ezrin Promotes Pancreatic Cancer Cell Proliferation and Invasion Through Activating the Akt/mTOR Pathway and Inducing YAP Translocation.

Ezrin-associated signal transduction in tumor invasion and metastasis

Association Between Ezrin Protein Expression and the Prognosis of Colorectal Adenocarcinoma.

Ezrin Overexpression Predicts the Poor Prognosis of Gastric Adenocarcinoma

Prognostic Implications of Ezrin and Phosphorylated Ezrin Expression in Non-Small Cell Lung Cancer

A retrospective analysis of ezrin protein and mRNA expression in breast cancer: Ezrin expression is associated with patient survival and survival of patients with receptor-positive disease

EZH2-mediated Epigenetic Activation of the CCL22/CCR4 Causing EMT Process Remodeling in Cervical Carcinoma